ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
A Cascaded DNA Nanocircuit for Multi-Signal-Responsive Precision siRNA Delivery in Cancer Therapy.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Precision control over nucleic acid delivery remains a critical challenge in cancer therapy, particularly for siRNA-based gene silencing, where off-target effects limit clinical translation. Herein, we report a programmably engineered DNA nanocircuit with cascaded dual-AND logic gates, which enables the development of a spatiotemporally controlled siRNA delivery strategy for precision cancer therapy. The DNA nanocircuit is engineered to respond to three tumor-specific signals in a sequential manner: extracellular acidic pH, membrane-overexpressed nucleolin (NCL), and intracellular glutathione (GSH). The first AND gate is activated by the co-occurrence of acidic pH and NCL, triggering a conformational rearrangement that generates a molecular output. This integrated output, combined with intracellular GSH, serves as the dual input to co-activate the second AND gate, initiating siRNA release via a cascade reaction inherent to the DNA circuit. As a proof-of-concept, when harnessing this DNA circuit in a temozolomide (TMZ)-resistant glioblastoma (GBM) mouse model, we demonstrate that this design ensures highly selective release of siPARP1 in GBM cells, achieving efficient PARP1 silencing, reversed TMZ resistance, and minimized off-target toxicity. Collectively, the cascaded dual-AND logic, enabled by precise DNA sequence programming, represents a generalizable strategy for multi-signal-responsive delivery systems, highlighting the potential of DNA circuits in precision cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.